2004 Oral Medicine/Pathology Research Award to Gutkind

March 10, 2004

Honolulu, Hawaii...Dr. J. Silvio Gutkind, a Senior Investigator in the National Institute of Dental and Craniofacial Research, National Institutes of Health (USA), and Chief of the Oral and Pharyngeal Cancer Branch, has been named the 2004 recipient of the Oral Medicine and Pathology Research Award, conferred by the International Association for Dental Research (IADR), convening here today for its 82nd General Session.

Dr. Gutkind received his PhD in pharmacy and biochemistry from the University of Buenos Aires, Argentina. He joined the National Cancer Institute, USA, in 1988, where he carried out research on the normal and oncogenic functions of non-receptor protein-tyrosine kinases. He subsequently moved to the National Institute of Dental and Craniofacial Research, where he established a new program addressing the molecular basis of cancer by studying normal and aberrant functions of molecules involved in the transduction of proliferative signals. His laboratory has made seminal contributions to the field, and helped elucidate some of the basic molecular mechanisms whereby cell-surface receptors regulate the nuclear expression of growth-promoting genes. In 1998, he was appointed as the Chief of the Oral and Pharyngeal Cancer Branch. He also heads a multi-institutional effort aimed to elucidate the molecular mechanisms that contribute to the evolution of squamous cell carcinomas, and to use this knowledge to develop molecular markers of disease progression and novel therapeutic approaches in oral malignancies.

Dr. Gutkind has been the recipient of numerous awards, including the National Institute of Dental Research Director's Exemplary Service Award and the National Institutes of Health Merit Award. He has published over 200 scientific papers, and contributed numerous review articles and book chapters addressing both basic molecular mechanisms and oral cancer research The IADR Oral Medicine and Pathology Research Award is supported Sunstar Butler and consists of a cash prize and a plaque. It is one of 15 Distinguished Scientist Awards given annually by the IADR.

Dr. Gutkind received his award today during the Opening Ceremonies of the IADR's 82nd General Session.
-end-
Press Counter
IADR Registration Area (Main Lobby)
Hawaii Convention Center
1801 Kalakaua Avenue
Honolulu, Hawaii 96815, USA
Main Switchboard: 808-943-3500

International & American Associations for Dental Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.